aspirin has been researched along with Non-ST-Elevation Myocardial Infarction in 30 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a randomized controlled trial to investigate whether an additional platelet inhibition with tirofiban would reduce the extent of myocardial damage and prevent periprocedural myonecrosis in patients with Non-ST-elevation acute coronary syndrome (NSTE-ACS) with a high residual platelet activity (HPR)." | 9.27 | Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial. ( Chae, IH; Cho, YS; Lee, W; Park, JJ; Suh, JW; Yoon, CH; Youn, TJ, 2018) |
| "All acute coronary syndrome patients from the REgistry of New Antiplatelets in patients with Myocardial Infarction (RENAMI) undergoing percutaneous coronary intervention and treated with aspirin, prasugrel or ticagrelor were stratified according to DAPT duration, that is, shorter than 12 months (D1 group), 12 months (D2 group) and longer than 12 months (D3 group)." | 7.96 | Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. ( Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Bertaina, M; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Fioravanti, F; Gaita, F; Gallo, D; Garay, A; Gili, S; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lüscher, TF; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Taha, S; Templin, C; Valdés, M; Varbella, F; Velicki, L; Xanthopoulou, I, 2020) |
| "We conducted a randomized controlled trial to investigate whether an additional platelet inhibition with tirofiban would reduce the extent of myocardial damage and prevent periprocedural myonecrosis in patients with Non-ST-elevation acute coronary syndrome (NSTE-ACS) with a high residual platelet activity (HPR)." | 5.27 | Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial. ( Chae, IH; Cho, YS; Lee, W; Park, JJ; Suh, JW; Yoon, CH; Youn, TJ, 2018) |
| "All acute coronary syndrome patients from the REgistry of New Antiplatelets in patients with Myocardial Infarction (RENAMI) undergoing percutaneous coronary intervention and treated with aspirin, prasugrel or ticagrelor were stratified according to DAPT duration, that is, shorter than 12 months (D1 group), 12 months (D2 group) and longer than 12 months (D3 group)." | 3.96 | Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. ( Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Bertaina, M; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Fioravanti, F; Gaita, F; Gallo, D; Garay, A; Gili, S; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lüscher, TF; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Taha, S; Templin, C; Valdés, M; Varbella, F; Velicki, L; Xanthopoulou, I, 2020) |
| "Between January 2012 and January 2017, 24 patients undergoing coronary angiography for stable coronary disease (7 cases) or acute coronary syndromes (non-ST-segment myocardial infarction [NSTEMI; 8 cases], STEMI [9 cases]) underwent aspirin desensitization having reported previous reactions to aspirin." | 3.91 | Rapid Aspirin Desensitization is Safe and Feasible in Patients With Stable and Unstable Coronary Artery Disease: A Single-Center Experience. ( Austin, D; Bolton, S; Callaghan, S; Carter, J; de Belder, MA; Hall, JA; Jackson, M; Muir, DF; Stapleton, J; Sutton, AGC; Swanson, N; Williams, PD; Wright, RA, 2019) |
| "Aspirin was administered to 180 (93." | 1.91 | Acute coronary syndrome in very elderly patients-a real-world experience. ( Baralis, G; Bianco, M; Cerrato, E; Cinconze, S; Giordana, F; Mottola, FF; Musumeci, G; Rossini, R; Verra, A, 2023) |
| "Predisposing conditions included fibromuscular dysplasia in 42." | 1.72 | Canadian Spontaneous Coronary Artery Dissection Cohort Study: 3-Year Outcomes. ( Alfadhel, M; Aymong, E; Bishop, H; Brass, N; Chaudhary, P; Ganesh, SK; Graham, J; Grewal, T; Har, B; Humphries, K; Ibrahim, R; Inohara, T; Ko, DT; Lavi, S; Lavoie, A; Madan, M; Mancini, GJ; Martucci, G; Matteau, A; McAlister, C; McGrath, BM; Minhas, K; Parolis, JA; Pearce, C; Renner, S; Samuel, R; Saw, J; Sheth, T; So, D; Starovoytov, A; Vijayaraghavan, R; Welsh, RC, 2022) |
| "The study consisted of 17 patients with STEMI referred for cardiac catheterisation post thrombolysis, and 20 patients with NSTEMI." | 1.48 | Measurement of microvascular function in patients presenting with thrombolysis for ST elevation myocardial infarction, and PCI for non-ST elevation myocardial infarction. ( Adams, H; Ashokkumar, S; Burns, AT; Judkins, C; La Gerche, A; Layland, J; MacIsaac, AI; Palmer, S; Whitbourn, RJ; Williams, PD; Wilson, AM, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (50.00) | 24.3611 |
| 2020's | 15 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, W | 1 |
| Du, X | 1 |
| Gao, Y | 1 |
| Hu, S | 1 |
| Lu, Y | 1 |
| Dreyer, RP | 1 |
| Li, X | 1 |
| Spatz, ES | 1 |
| Masoudi, FA | 1 |
| Krumholz, HM | 1 |
| Zheng, X | 1 |
| Moledina, SM | 1 |
| Mannan, F | 1 |
| Weight, N | 1 |
| Alisiddiq, Z | 1 |
| Elbadawi, A | 1 |
| Elgendy, IY | 1 |
| Fischman, DL | 1 |
| Mamas, MA | 2 |
| Nadarajah, R | 1 |
| Ludman, P | 1 |
| Appelman, Y | 1 |
| Brugaletta, S | 1 |
| Budaj, A | 1 |
| Bueno, H | 1 |
| Huber, K | 2 |
| Kunadian, V | 1 |
| Leonardi, S | 1 |
| Lettino, M | 1 |
| Milasinovic, D | 1 |
| Gale, CP | 1 |
| Saw, J | 1 |
| Starovoytov, A | 1 |
| Aymong, E | 1 |
| Inohara, T | 1 |
| Alfadhel, M | 1 |
| McAlister, C | 1 |
| Samuel, R | 1 |
| Grewal, T | 1 |
| Parolis, JA | 1 |
| Sheth, T | 1 |
| So, D | 1 |
| Minhas, K | 1 |
| Brass, N | 1 |
| Lavoie, A | 1 |
| Bishop, H | 1 |
| Lavi, S | 1 |
| Pearce, C | 1 |
| Renner, S | 1 |
| Madan, M | 1 |
| Welsh, RC | 1 |
| McGrath, BM | 1 |
| Vijayaraghavan, R | 1 |
| Har, B | 1 |
| Ibrahim, R | 1 |
| Chaudhary, P | 1 |
| Ganesh, SK | 1 |
| Graham, J | 1 |
| Matteau, A | 1 |
| Martucci, G | 1 |
| Ko, DT | 1 |
| Humphries, K | 1 |
| Mancini, GJ | 1 |
| Greco, A | 1 |
| Finocchiaro, S | 1 |
| Angiolillo, DJ | 1 |
| Capodanno, D | 1 |
| Bianco, M | 1 |
| Mottola, FF | 1 |
| Cerrato, E | 2 |
| Giordana, F | 1 |
| Cinconze, S | 1 |
| Baralis, G | 1 |
| Verra, A | 1 |
| Musumeci, G | 1 |
| Rossini, R | 1 |
| Dracoulakis, MDA | 1 |
| Gurbel, P | 1 |
| Cattaneo, M | 1 |
| Martins, HS | 1 |
| Nicolau, JC | 1 |
| Kalil Filho, R | 1 |
| Gimbel, ME | 1 |
| Vos, GJA | 1 |
| Nguyen, TA | 1 |
| Kelder, JC | 1 |
| Ten Berg, JM | 1 |
| Akhter, Z | 1 |
| Rind, IA | 1 |
| Aijaz, S | 1 |
| Sattar, S | 1 |
| Malik, R | 1 |
| Pathan, A | 1 |
| Dickson, SD | 1 |
| Taleb, A | 1 |
| Wiernek, S | 1 |
| Govea, A | 1 |
| Penny, W | 1 |
| Khan, N | 1 |
| Moss, A | 1 |
| Gorog, DA | 1 |
| Nightingale, P | 1 |
| Armesilla, A | 1 |
| Smallwood, A | 1 |
| Munir, S | 1 |
| Khogali, S | 1 |
| Wrigley, B | 1 |
| Cotton, JM | 1 |
| Regragui, H | 1 |
| Boussaadani, BE | 1 |
| Sasbou, L | 1 |
| Bouhdadi, H | 1 |
| Wazaren, H | 1 |
| Cherti, M | 1 |
| Fagel, ND | 1 |
| Amoroso, G | 1 |
| Vink, MA | 1 |
| Slagboom, T | 1 |
| van der Schaaf, RJ | 1 |
| Herrman, JP | 1 |
| Patterson, MS | 1 |
| Oosterwerff, EFJ | 1 |
| Vos, NS | 1 |
| Verheugt, FWA | 1 |
| Tijssen, JGP | 1 |
| de Winter, RJ | 1 |
| Riezebos, RK | 1 |
| Clarkson, SA | 1 |
| Heindl, B | 1 |
| Cai, A | 1 |
| Beasley, M | 1 |
| Dillon, C | 1 |
| Limdi, N | 1 |
| Brown, TM | 1 |
| Tang, X | 1 |
| Liu, L | 1 |
| Yang, J | 1 |
| Gao, Z | 1 |
| Zhao, X | 1 |
| Qiao, S | 1 |
| Gao, R | 1 |
| Wang, Z | 1 |
| Yuan, J | 1 |
| Yang, Y | 1 |
| Kern, A | 1 |
| Gil, RJ | 1 |
| Bojko, K | 1 |
| Sienkiewicz, E | 1 |
| Januszko-Giergielewicz, B | 1 |
| Górny, J | 1 |
| Bil, J | 1 |
| Palmer, S | 1 |
| Layland, J | 1 |
| Adams, H | 1 |
| Ashokkumar, S | 1 |
| Williams, PD | 2 |
| Judkins, C | 1 |
| La Gerche, A | 1 |
| Burns, AT | 1 |
| Whitbourn, RJ | 1 |
| MacIsaac, AI | 1 |
| Wilson, AM | 1 |
| Denlinger, LN | 1 |
| Keeley, EC | 1 |
| Gibler, WB | 1 |
| Racadio, JM | 1 |
| Hirsch, AL | 1 |
| Roat, TW | 1 |
| Lee, W | 1 |
| Suh, JW | 1 |
| Park, JJ | 1 |
| Yoon, CH | 1 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Chae, IH | 1 |
| Jackson, M | 1 |
| Callaghan, S | 1 |
| Stapleton, J | 1 |
| Bolton, S | 1 |
| Austin, D | 1 |
| Muir, DF | 1 |
| Sutton, AGC | 1 |
| Wright, RA | 1 |
| Hall, JA | 1 |
| Carter, J | 1 |
| de Belder, MA | 1 |
| Swanson, N | 1 |
| D'Ascenzo, F | 1 |
| Bertaina, M | 1 |
| Fioravanti, F | 1 |
| Bongiovanni, F | 1 |
| Raposeiras-Roubin, S | 1 |
| Abu-Assi, E | 1 |
| Kinnaird, T | 1 |
| Ariza-Solé, A | 1 |
| Manzano-Fernández, S | 1 |
| Templin, C | 1 |
| Velicki, L | 1 |
| Xanthopoulou, I | 1 |
| Rognoni, A | 1 |
| Boccuzzi, G | 1 |
| Omedè, P | 1 |
| Montabone, A | 1 |
| Taha, S | 1 |
| Durante, A | 1 |
| Gili, S | 1 |
| Magnani, G | 1 |
| Autelli, M | 1 |
| Grosso, A | 1 |
| Blanco, PF | 1 |
| Garay, A | 1 |
| Quadri, G | 1 |
| Varbella, F | 1 |
| Queija, BC | 1 |
| Paz, RC | 1 |
| Fernández, MC | 1 |
| Pousa, IM | 1 |
| Gallo, D | 1 |
| Morbiducci, U | 1 |
| Dominguez-Rodriguez, A | 1 |
| Valdés, M | 1 |
| Cequier, A | 1 |
| Alexopoulos, D | 1 |
| Iñiguez-Romo, A | 1 |
| Gaita, F | 1 |
| Rinaldi, M | 1 |
| Lüscher, TF | 1 |
| Hawatmeh, A | 1 |
| Thawabi, M | 1 |
| Aggarwal, R | 1 |
| Abirami, C | 1 |
| Vavilin, I | 1 |
| Wasty, N | 1 |
| Visveswaran, G | 1 |
| Cohen, M | 1 |
| Valle, JA | 1 |
| Josey, K | 1 |
| Prouse, AF | 1 |
| Zimmet, J | 1 |
| Waldo, SW | 1 |
| Tscharre, M | 1 |
| Farhan, S | 1 |
| Bruno, V | 1 |
| Rohla, M | 1 |
| Egger, F | 1 |
| Weiss, TW | 1 |
| Hübl, W | 1 |
| Willheim, M | 1 |
| Wojta, J | 1 |
| Geppert, A | 1 |
| Freynhofer, MK | 1 |
| Hagström, E | 1 |
| Roe, MT | 2 |
| Hafley, G | 1 |
| Neely, ML | 1 |
| Sidhu, MS | 1 |
| Winters, KJ | 1 |
| Prabhakaran, D | 2 |
| White, HD | 2 |
| Armstrong, PW | 2 |
| Fox, KA | 2 |
| Ohman, EM | 2 |
| Boden, WE | 1 |
| Smilowitz, NR | 1 |
| Weiss, MC | 1 |
| Mauricio, R | 1 |
| Mahajan, AM | 1 |
| Dugan, KE | 1 |
| Devanabanda, A | 1 |
| Pulgarin, C | 1 |
| Gianos, E | 1 |
| Shah, B | 1 |
| Sedlis, SP | 1 |
| Radford, M | 1 |
| Reynolds, HR | 1 |
| Wang, L | 1 |
| Bi, Y | 1 |
| Cao, M | 1 |
| Ma, R | 1 |
| Wu, X | 1 |
| Zhang, Y | 2 |
| Ding, W | 1 |
| Liu, Y | 1 |
| Yu, Q | 1 |
| Jiang, H | 1 |
| Sun, Y | 1 |
| Tong, D | 1 |
| Guo, L | 1 |
| Dong, Z | 1 |
| Tian, Y | 1 |
| Kou, J | 1 |
| Shi, J | 1 |
| Makam, RC | 1 |
| Erskine, N | 1 |
| McManus, DD | 1 |
| Lessard, D | 1 |
| Gore, JM | 1 |
| Yarzebski, J | 1 |
| Goldberg, RJ | 1 |
| Cornel, JH | 1 |
| Neely, B | 1 |
| Jakubowski, JA | 1 |
| Bhatt, DL | 1 |
| Ardissino, D | 1 |
| Erlinge, D | 1 |
| Tantry, US | 1 |
| Gurbel, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction[NCT01624883] | 18,000 participants (Actual) | Observational | 2012-04-30 | Completed | |||
| Naples Federico II Intensive Cardiac Care Unit Registry (Naples FED2-ICCU Registry)[NCT06162247] | 5,000 participants (Anticipated) | Observational | 2023-11-20 | Recruiting | |||
| Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention[NCT03114995] | Phase 4 | 140 participants (Actual) | Interventional | 2012-02-01 | Completed | ||
| A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998] | Phase 3 | 9,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Hours*ng/ml (Median) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 38.0 | 92.7 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 121.4 | 185.6 |
| Group A (High Platelet Reactivity - Tirofiban) | 197.2 | 252.5 |
"Percentage of participants with periprocedural myonecrosis under the criteria described below.~When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis." (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 15 | 10 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 26 | 25 |
| Group A (High Platelet Reactivity - Tirofiban) | 16 | 11 |
The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.61 |
| Prasugrel: 75 Years of Age or Older | 27.04 |
| Clopidogrel: <75 Years of Age | 11.12 |
| Clopidogrel: 75 Years of Age or Older | 26.83 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.06 |
| Prasugrel: 75 Years of Age or Older | 24.64 |
| Clopidogrel: <75 Years of Age | 10.96 |
| Clopidogrel: 75 Years of Age or Older | 24.13 |
The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 9.61 |
| Prasugrel: 75 Years of Age or Older | 22.53 |
| Clopidogrel: <75 Years of Age | 10.21 |
| Clopidogrel: 75 Years of Age or Older | 22.69 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 12.13 |
| Prasugrel: 75 Years of Age or Older | 26.27 |
| Clopidogrel: <75 Years of Age | 12.83 |
| Clopidogrel: 75 Years of Age or Older | 25.67 |
Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months
| Intervention | picograms per milliliter (pg/mL) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=725, 125, 701, 174) | |
| Clopidogrel: <75 Years of Age | 319.345 | 250.982 |
| Clopidogrel: 75 Years of Age or Older | 951.359 | 722.750 |
| Prasugrel: <75 Years of Age | 313.494 | 253.434 |
| Prasugrel: 75 Years of Age or Older | 1082.396 | 770.132 |
C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6
| Intervention | milligrams per liter (mg/L) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=755, 143, 745, 178) | |
| Clopidogrel: <75 Years of Age | 2.287 | 2.149 |
| Clopidogrel: 75 Years of Age or Older | 2.226 | 1.543 |
| Prasugrel: <75 Years of Age | 2.330 | 2.272 |
| Prasugrel: 75 Years of Age or Older | 2.441 | 1.593 |
Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline, physical limitations | Baseline, angina frequency | 24 Months, physical limitations (n=420, 412) | 24 Months, angina frequency (n=420, 412) | |
| Clopidogrel | 67.0 | 73.1 | 74.5 | 89.5 |
| Prasugrel | 67.8 | 73.6 | 75.1 | 89.7 |
Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline
| Intervention | percentage participants with geneotype (Number) | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UM, *1/*17 | UM, *17/*17 | EM (non-UM), *1/*1 | IM, *1/*2 | IM, *1/*3 | IM, *1/*4 | IM, *1/*6 | IM, *1/*8 | PM, *2/*2 | PM, *2/*3 | PM, *2/*4 | PM, *2/*6 | PM, *2/*8 | PM, *3/*3 | UNK, *1/*10 | UNK, *1/*13 | UNK, *1/*9 | UNK, *1/*9, *9/*17 | UNK, *13/*17 | UNK, *2/*13 | UNK, *2/*17 | UNK, *2/*9 | UNK, *3/*17 | UNK, *4/*17 | UNK, *4/*9 | UNK, *6/*17 | UNK, *8/*17 | UNK, *9/*17 | UNK, Undefined genotype | |
| Clopidogrel: <75 Years of Age | 25.1 | 5.4 | 35.7 | 19.8 | 0.5 | 0.1 | 0.0 | 0.4 | 4.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.8 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.5 |
| Clopidogrel: 75 Years of Age or Older | 21.8 | 4.3 | 41.2 | 19.7 | 0.6 | 0.3 | 0.2 | 0.3 | 3.8 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.2 | 0.0 | 0.3 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.6 |
| Prasugrel: <75 Years of Age | 24.0 | 5.1 | 38.8 | 18.6 | 0.8 | 0.4 | 0.0 | 0.1 | 3.9 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 6.3 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.7 |
| Prasugrel: 75 Years of Age or Older | 25.0 | 3.6 | 42.1 | 18.3 | 0.6 | 0.0 | 0.2 | 0.5 | 2.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 6.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months
| Intervention | P2Y12 Reaction Units (PRU) (Least Squares Mean) | |
|---|---|---|
| Day 30 | Month 12 (n=386, 76, 400, 103) | |
| Clopidogrel: <75 Years of Age | 193.489 | 199.003 |
| Clopidogrel: 75 Years of Age or Older | 200.285 | 181.360 |
| Prasugrel: <75 Years of Age | 93.280 | 94.529 |
| Prasugrel: 75 Years of Age or Older | 151.872 | 135.096 |
All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congestive Heart Failure | Cardiogenic Shock | Cardiac Rupture | Myocardial Infarction | Dysrhythmia | Stent Thrombosis | Directly Related to Revascularization-CABG or PCI | Intracranial Hemorrhage | Non-Hemorrhagic Stroke | Sudden death due to cardiovascular event | Pulmonary Embolism | Stroke, unknown type | Other Cardiovascular Event | Cardiovascular event, unknown type | Accidental | Trauma | Hemorrhage, not intracranial | Infection | Malignancy | Suicide | Other Non-Cardiovascular event | Cause unknown (nonadjudicated event) | |
| Clopidogrel: <75 Years of Age | 13 | 10 | 0 | 24 | 6 | 0 | 1 | 4 | 4 | 70 | 2 | 0 | 0 | 45 | 1 | 0 | 0 | 16 | 14 | 0 | 8 | 0 |
| Clopidogrel: 75 Years of Age or Older | 23 | 9 | 0 | 21 | 3 | 0 | 1 | 1 | 3 | 43 | 1 | 0 | 1 | 45 | 1 | 1 | 4 | 17 | 11 | 0 | 6 | 0 |
| Prasugrel: <75 Years of Age | 10 | 8 | 0 | 16 | 5 | 0 | 1 | 2 | 4 | 75 | 0 | 0 | 6 | 40 | 1 | 2 | 1 | 14 | 14 | 1 | 8 | 0 |
| Prasugrel: 75 Years of Age or Older | 21 | 4 | 1 | 24 | 2 | 0 | 1 | 1 | 4 | 39 | 1 | 1 | 1 | 41 | 0 | 3 | 1 | 21 | 7 | 0 | 4 | 1 |
2 reviews available for aspirin and Non-ST-Elevation Myocardial Infarction
| Article | Year |
|---|---|
Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
Topics: Acute Coronary Syndrome; Arrhythmias, Cardiac; Aspirin; Fibrinolytic Agents; Humans; Lipids; Non-ST | 2023 |
Continuum of Care for Acute Coronary Syndrome: Optimizing Treatment for ST-Elevation Myocardial Infarction and Non-St-Elevation Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aftercare; Aspirin; Cardiac Catheterization; Continuity of Patient Care; Co | 2018 |
4 trials available for aspirin and Non-ST-Elevation Myocardial Infarction
| Article | Year |
|---|---|
Sex Differences in Characteristics, Treatments, and Outcomes Among Patients Hospitalized for Non-ST-Segment-Elevation Myocardial Infarction in China: 2006 to 2015.
Topics: Aspirin; China; Female; Healthcare Disparities; Humans; Male; Non-ST Elevated Myocardial Infarction; | 2022 |
An immediate or early invasive strategy in non-ST-elevation acute coronary syndrome: The OPTIMA-2 randomized controlled trial.
Topics: Aged; Area Under Curve; Aspirin; Cause of Death; Combined Modality Therapy; Coronary Angiography; Cr | 2021 |
Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Coronary Angiogr | 2018 |
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Biomarkers; Cholesterol, HDL; Clopidogrel; | 2016 |
24 other studies available for aspirin and Non-ST-Elevation Myocardial Infarction
| Article | Year |
|---|---|
Impact of QRS Duration on Non-ST-Segment Elevation Myocardial Infarction (from a National Registry).
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Humans; M | 2022 |
Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Hospital | 2022 |
Canadian Spontaneous Coronary Artery Dissection Cohort Study: 3-Year Outcomes.
Topics: Adult; Aftercare; Aspirin; Canada; Cohort Studies; Coronary Angiography; Coronary Vessels; Female; F | 2022 |
Acute coronary syndrome in very elderly patients-a real-world experience.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; | 2023 |
High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelet Disorders; Blood Platelets; Female; Humans; M | 2019 |
Reasons for early discontinuing or switching of antiplatelet therapy in elderly patients after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Bypass; Depr | 2020 |
Management, hospital outcome and revascularization trends in non-ST elevation myocardial infarction with high GRACE risk score.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2019 |
Diffuse saphenous vein graft thrombosis: resolution after one month of apixaban and dual antiplatelet therapy.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Graft Occlusion, Vascular; | 2020 |
Aspirin related platelet reactivity as a determinant of ten year survival in high risk non-ST segment elevation myocardial infarction (NSTEMI) patients.
Topics: Aspirin; Blood Platelets; Electrocardiography; Hospital Mortality; Humans; Myocardial Infarction; No | 2020 |
Conservative management of spontaneous coronary artery dissection: a case report.
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Computed Tomography Angiography; Conservative Treatment | 2020 |
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Case-Control Studies; Clopidogrel; Diabete | 2021 |
Evidence-based oral antiplatelet therapy among hospitalized Chinese patients with acute myocardial infarction: results from the Chinese acute myocardial infarction registry.
Topics: Administration, Oral; Aged; Aspirin; China; Clopidogrel; Drug Utilization; Dual Anti-Platelet Therap | 2021 |
Platelet distribution width as the prognostic marker in coronary bifurcation treatment.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; H | 2017 |
Measurement of microvascular function in patients presenting with thrombolysis for ST elevation myocardial infarction, and PCI for non-ST elevation myocardial infarction.
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Coronary Circulation; Coronary Vessels; Echocardiogra | 2018 |
Medication Administration Delays in Non-ST Elevation Myocardial Infarction: Analysis of 1002 Patients Admitted to an Academic Medical Center.
Topics: Academic Medical Centers; Adrenergic beta-Antagonists; Age Factors; Aged; American Heart Association | 2018 |
Rapid Aspirin Desensitization is Safe and Feasible in Patients With Stable and Unstable Coronary Artery Disease: A Single-Center Experience.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Desensitization, Immunologic; Drug Hypers | 2019 |
Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Administration Schedule; Dual Anti-Platelet Therapy; Eu | 2020 |
Implications of Misclassification of Type 2 Myocardial Infarction on Clinical Outcomes.
Topics: Age Factors; Aged; Aspirin; Comorbidity; Diagnostic Errors; Female; Humans; Hydroxymethylglutaryl-Co | 2020 |
Dual antiplatelet therapy in non-ST elevation acute coronary syndromes at Veterans Affairs Hospitals.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Dual Anti-Platelet Therapy; Female; Humans; Male; | 2019 |
Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Diseas | 2019 |
Provoking conditions, management and outcomes of type 2 myocardial infarction and myocardial necrosis.
Topics: Aged; Aged, 80 and over; Aspirin; Electrocardiography; Female; Hospital Mortality; Humans; Hydroxyme | 2016 |
Microparticles and blood cells induce procoagulant activity via phosphatidylserine exposure in NSTEMI patients following stent implantation.
Topics: Aged; Aspirin; Blood Cells; Blood Coagulation; Cell-Derived Microparticles; Clopidogrel; Female; Hum | 2016 |
Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2016 |
Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy | 2016 |